Center for Biologics Evaluation and Research, FDA
American Association of Blood Banks
America's Blood Centers
National Heart, Lung, and Blood Institute, NIH
U.S. Department of Defense
U.S. Department of Health and Human Services
| 8:00 AM | Registration |
| 8:30 AM | Welcome Address Peter W. Marks, MD, PhD - FDA |
| 8:40 AM | Announcements, Objectives, and FDA Perspective on Emerging Tick-Borne Diseases David A. Leiby, PhD - FDA |
| 8:55 AM | Plenary Presentation on Tick-Borne Diseases Peter J. Krause, MD – Yale University |
Session 1: Biology, Epidemiology and Clinical Burden of HGA | |
| 9:30 AM | Anaplasma phagocytophilum, etiologic agent of human granulocytic anaplasmosis Cara Cherry, DVM, MPH - CDC |
| 9:55 AM | Clinical Aspects of HGA J. Stephen Dumler, MD - USUHS |
| 10:20 AM | Coffee Break– Sponsored by AABB |
Session 2: Biology, Epidemiology and Clinic Burden of Other Emerging Tick-Borne Agents | |
| 10:50 AM | Other Emerging Tick-Borne Agents Sam R. Telford III, PhD – Tufts University |
| 11:20 AM | State's Perspective on Burgeoning Tick-borne Diseases Alfred DeMaria, Jr., MD – Massachusetts Department of Health |
| 11:50 AM | Round Table Discussion I Morning speakers; Bryan R. Spencer, MPH – American Red Cross; and Hira L. Nakhasi, PhD - FDA |
| 12:20 PM | Lunch |
Session 3: Transfusion Transmission | |
| 1:20 PM | Transmission Risks Posed by Emergent Agents David A. Leiby, PhD - FDA |
| 1:45 PM | Incidence of Transfusion Transmission (HGA and Other Agents) Susan L. Stramer, PhD – American Red Cross |
| 2:10 PM | Coffee Break– Sponsored by America's Blood Centers |
Session 4: Mitigation Efforts | |
| 2:40 PM | Mitigation Strategies Lou Katz, MD – America's Blood Centers |
| 3:10 PM | Conceptual Framework for Test Development Raymond P. Goodrich, PhD – Colorado State University |
| 3:40 PM | Risk Based Decision Making: The ABO Approach Judie Leach Bennet, LLM – Canadian Blood Services |
| 4:10 PM | Roundtable Discussion II Afternoon speakers; CAPT Roland L. Fahie - DoD; Roger Y. Dodd, PhD – American Red Cross; and Jay S. Epstein, MD - FDA |
| 5:00 PM | Summary & Wrap-up David A. Leiby, PhD - FDA |
| 5:15 PM | Adjourn |
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
